Evidence map›Paper›PMID 30811584›Full record

ArticleBritish journal of pharmacology2019

The MC

Shengpan Chen, Yuchun Zuo, Lei Huang, Prativa Sherchan, Jian Zhang, Zhengtao Yu, Jianhua Peng, Junyi Zhang, Lianhua Zhao, Desislava Doycheva and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Shengpan ChenDepartment of Neurosurgery, Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou, China.
Yuchun ZuoDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Lei HuangDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Prativa SherchanDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Jian ZhangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Zhengtao YuDepartment of Neurosurgery, Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou, China.
Jianhua PengDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Junyi ZhangDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Lianhua ZhaoDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Desislava DoychevaDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Fei LiuDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, Changsha, China.
John H ZhangDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Ying XiaDepartment of Neurosurgery, Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou, China.
Jiping TangDepartment of Physiology, School of Medicine, Loma Linda University, Loma Linda, CA, USA.ORCID 0000-0002-2392-9280
Central South University · CNLoma Linda University · USLoma Linda University Medical Center · US

Funding

Vascular Biology Core FacilityP01NS082184 · NINDS · LOMA LINDA UNIVERSITY · PI PEARCE, WILLIAM J. · 2014 to 2018
$6.1M
Harnessing Endogenous Neuroprotection Following ICHR01NS091042 · NINDS · LOMA LINDA UNIVERSITY · PI ZHANG, JOHN H · 2016 to 2020
$1.7M
NINDS NIH HHS P01 NS082184NINDS NIH HHS R01 NS091042
6 · The paper itself

Abstract

background and purposeInflammasome-mediated pyroptosis is an important neuronal cell death mechanism. Previous studies reported that activation of melanocortin MC EXPERIMENTAL APPROACH: One hundred and sixty-nine male CD1 mice were used. ICH was induced by injection of bacterial collagenase into the right-side basal ganglia. RO27-3225, a selective agonist of MC KEY

resultsExpression of MC CONCLUSIONS AND IMPLICATIONS: RO27-3225 suppressed NLRP1-dependent neuronal pyroptosis and improved neurological function, possibly mediated by activation of MC

Indexed as

Disease Models, AnimalAdaptor Proteins, Signal TransducingAnimalsApoptosis Regulatory ProteinsCerebral HemorrhageJNK Mitogen-Activated Protein KinasesMaleMAP Kinase Kinase Kinase 5MiceNeuronsp38 Mitogen-Activated Protein KinasesPeptidesReceptor, Melanocortin, Type 4Signal TransductionAdaptor Proteins, Signal TransducingApoptosis Regulatory Proteinsbutir-His-Phe-Arg-Trp-Sar-NH2JNK Mitogen-Activated Protein KinasesMap3k5 protein, mouseMAP Kinase Kinase Kinase 5MC4R protein, mouseNALP1 protein, mousep38 Mitogen-Activated Protein KinasesPeptidesReceptor, Melanocortin, Type 4

Identifiers

PMID30811584
PMCPMC6468256
OpenAlexW2916509418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.